Work at Argenx BV.

Healthcare Biotechnology Clinical Trials Therapeutics

Open roles 4

Founded 2008

Type Public · ARGX

Team size 1,001–5,000

Headquarters Boston

Website argenx.com

Legal name argenx SE

View on LinkedIn →

Open roles at Argenx BV

4 open roles

Digital Technology Computer System Assurance Expert United States · United States Salary TBC 10 days ago

Senior Director, Patient Marketing Excellence Lead Boston · Boston Salary TBC 20 days ago

Head of Commercial Analytics & Insights United Kingdom · United Kingdom Salary TBC 53 days ago

Senior Director, Commercialization Strategy & Operations Enablement Boston · Boston Salary TBC 60 days ago

About Argenx BV

argenx is a global biotechnology company focused on discovering and developing immunology medicines, with its lead product VYVGART and a pipeline of differentiated therapies for autoimmune and other severe immune-mediated diseases. The company is publicly listed and has a major operational presence in Ghent, Belgium, while its corporate headquarters are in Amsterdam, the Netherlands.

Products & services

VYVGART® (efgartigimod alfa-fcab) An intravenous FcRn antagonist approved in the United States for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive.
VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) A subcutaneous efgartigimod formulation approved for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy in the United States.
Efgartigimod An FcRn-blocking antibody fragment marketed as VYVGART products and being investigated for additional severe autoimmune diseases driven by pathogenic IgG antibodies.
Empasiprubart A clinical-stage humanized sweeping antibody designed to inhibit complement component C2 and downstream complement activation in severe IgM-driven autoimmune diseases.
ARGX-119 An investigational product candidate in clinical development for severe autoimmune diseases; the crawled source does not specify its molecular target or mechanism.
ARGX-118 An investigational antibody targeting Galectin-10, designed to dissolve Charcot-Leyden crystals and address airway inflammation in severe eosinophilic respiratory disease.

Leadership

Karen Massey Chief Executive Officer
Hans De Haard Co founder
Eric Castaldi Chief Financial Officer
Tom Hughes HEOR Launch Consultant
Tim Van Hauwermeiren Founder

Work at Argenx BV.

Open roles at Argenx BV

Subscribe to Career Resources.

Your cookie choices